Bio-Techne Reports Earnings Growth in Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy TECH?
Source: NASDAQ.COM
- Earnings Growth: Bio-Techne's net income for Q2 reached $38 million, translating to an earnings per share (EPS) of $0.24, which is an increase from last year's $34.89 million and $0.22 EPS, indicating improved profitability.
- Adjusted Earnings: Excluding certain items, Bio-Techne reported adjusted earnings of $72.11 million, or $0.46 per share, demonstrating strong performance in core operations despite a slight decline in overall revenue.
- Slight Revenue Decline: The company's total revenue for the quarter was $295.87 million, down 0.4% from $297.03 million last year, reflecting challenges in the market environment while maintaining a relatively stable revenue level.
- Financial Overview: Bio-Techne's financial data indicates that despite a decrease in revenue, the increase in profitability and adjusted earnings growth may provide confidence for future investors, showcasing the company's competitiveness in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 59.540
Low
60.00
Averages
66.14
High
72.00
Current: 59.540
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne's Ella Platform Receives CE-IVD Certification
- CE-IVD Certification Achieved: Bio-Techne's Ella immunoassay platform has received CE-IVD marking and is now available for sale in the EU, marking a significant advancement in precision diagnostics that enhances clinical decision-making efficiency and accuracy.
- Ease of Use Enhanced: The Ella system delivers accurate biomarker results in under 90 minutes while simplifying traditional immunoassay manual steps, thereby reducing operator variability and ensuring high-quality, reproducible data suitable for both translational research and clinical applications.
- Wide Application Compatibility: The Ella platform is compatible with Simple Plex™ assays, covering over 390 analytes across neuroscience, immunology, and oncology, enabling researchers to maintain data consistency and quality while working efficiently across various applications.
- Advancing Precision Medicine Goals: The CE-IVD certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal of providing reliable, standardized solutions for biomarker detection, facilitating clinical trials and in-house test development.
See More
Bio-Techne's Ella Platform Receives CE-IVD Marking
- CE-IVD Certification Achieved: Bio-Techne's Ella platform has received CE-IVD marking and is now available for sale in the EU, marking a significant advancement in precision diagnostics and enhancing its application potential in clinical trials and in-house test development.
- Rapid Testing Capability: The Ella system delivers accurate biomarker results in under 90 minutes, simplifying manual steps of traditional immunoassays, thereby reducing operator variability and improving data reproducibility to support timely clinical decision-making.
- Wide Application Compatibility: The platform is compatible with Simple Plex™ assays, covering over 390 analytes across neuroscience, immunology, and oncology, ensuring researchers maintain data quality and consistency across various applications, thus promoting standardization in biomarker detection.
- Strategic Implications: The CE-IVD certification of Ella not only enhances confidence in its performance but also supports Bio-Techne's long-term goal in precision medicine by providing reliable solutions aimed at improving clinical outcomes for patients.
See More
Amazon Plans Significant Capital Expenditure Increase
- Capital Expenditure Increase: Amazon announced in its latest earnings report that it will raise its capital expenditure for 2026 to $200 billion from approximately $130 billion in 2025, indicating strong confidence in future growth while raising investor concerns over high spending.
- Stock Price Volatility: Although Amazon shares rose 0.27% on Friday, they have declined about 17.5% over the past month and are hovering near their lowest level since May 2025, reflecting market caution regarding the company's future performance.
- Market Sentiment Shift: Retail sentiment on Stocktwits has shifted from 'extremely bullish' to 'bullish' in the past 24 hours, with a 35% increase in discussions, indicating a divergence in investor opinions about the stock's trajectory.
- Industry Investment Trends: Amazon's capital expenditure plans align with other major tech companies, which collectively plan to invest over $630 billion in AI buildouts in 2026, highlighting strong expectations for AI demand despite investor concerns about massive expenditures.
See More
Bio-Techne Corporation Q2 2026 Earnings Insights
- Stable Performance: Bio-Techne reported total revenue of $295.9 million for Q2, flat year-over-year, despite headwinds from two large cell therapy customers with FDA Fast Track designations, indicating a balance of short-term challenges and long-term potential in the market.
- Margin Improvement: Adjusted operating margins expanded by approximately 100 basis points year-over-year to 31.1%, reflecting effective strategies in cost management and product mix optimization, which are expected to further enhance profitability in the future.
- Core Business Growth: The four key verticals—cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools—now represent 47% of total revenue, up from 32% in fiscal 2020, demonstrating the company's agile response to strategic investments and changing market demands.
- Outlook: Management anticipates that Q3 organic growth will be consistent with Q2; however, excluding customer-specific cell therapy and OEM headwinds, underlying growth for the remainder of the business is expected to reach mid-single digits, reflecting confidence in future market recovery.
See More
Bio-Techne Declares Quarterly Dividend of $0.08
- Dividend Stability: Bio-Techne declares a quarterly dividend of $0.08 per share, maintaining this amount for 46 consecutive quarters, which demonstrates the company's reliability in shareholder returns and enhances investor confidence.
- Yield Performance: The forward yield of 0.5% may be relatively low, yet it still provides an attractive option for income-seeking investors in the current market environment, potentially encouraging long-term shareholder retention.
- Payment Schedule: The dividend is payable on February 27, with a record date of February 16 and an ex-dividend date of February 12, providing investors with clear cash flow expectations that may enhance market liquidity.
- Financial Performance Beat: Bio-Techne's recent non-GAAP EPS of $0.46 exceeded expectations by $0.03, with revenue of $295.88M surpassing estimates by $5.41M, indicating the company's ongoing growth potential in both revenue and profitability.
See More
Bio-Techne Q2 Earnings Exceed Expectations
- Strong Earnings Performance: Bio-Techne reported a Q2 Non-GAAP EPS of $0.46, beating expectations by $0.03, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Slight Revenue Decline: The revenue of $295.88 million, down 0.4% year-over-year, still surpassed market expectations by $5.41 million, indicating the company's ability to maintain relatively stable revenue performance amid challenges.
- Operational Efficiency Improvement: The adjusted operating margin reached 31.1%, an increase of 100 basis points compared to the prior year, showcasing effective productivity and cost containment measures that further enhance profitability.
- Growth in APAC Market: Strong commercial execution and improving market conditions in China and the APAC region led to growth for the third consecutive quarter, demonstrating the ongoing potential of this market segment.
See More
Bio-Techne's Ella Platform Receives CE-IVD Certification
- CE-IVD Certification Achieved: Bio-Techne's Ella immunoassay platform has received CE-IVD marking and is now available for sale in the EU, marking a significant advancement in precision diagnostics that enhances clinical decision-making efficiency and accuracy.
- Ease of Use Enhanced: The Ella system delivers accurate biomarker results in under 90 minutes while simplifying traditional immunoassay manual steps, thereby reducing operator variability and ensuring high-quality, reproducible data suitable for both translational research and clinical applications.
- Wide Application Compatibility: The Ella platform is compatible with Simple Plex™ assays, covering over 390 analytes across neuroscience, immunology, and oncology, enabling researchers to maintain data consistency and quality while working efficiently across various applications.
- Advancing Precision Medicine Goals: The CE-IVD certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal of providing reliable, standardized solutions for biomarker detection, facilitating clinical trials and in-house test development.
See More
Bio-Techne's Ella Platform Receives CE-IVD Marking
- CE-IVD Certification Achieved: Bio-Techne's Ella platform has received CE-IVD marking and is now available for sale in the EU, marking a significant advancement in precision diagnostics and enhancing its application potential in clinical trials and in-house test development.
- Rapid Testing Capability: The Ella system delivers accurate biomarker results in under 90 minutes, simplifying manual steps of traditional immunoassays, thereby reducing operator variability and improving data reproducibility to support timely clinical decision-making.
- Wide Application Compatibility: The platform is compatible with Simple Plex™ assays, covering over 390 analytes across neuroscience, immunology, and oncology, ensuring researchers maintain data quality and consistency across various applications, thus promoting standardization in biomarker detection.
- Strategic Implications: The CE-IVD certification of Ella not only enhances confidence in its performance but also supports Bio-Techne's long-term goal in precision medicine by providing reliable solutions aimed at improving clinical outcomes for patients.
See More
Amazon Plans Significant Capital Expenditure Increase
- Capital Expenditure Increase: Amazon announced in its latest earnings report that it will raise its capital expenditure for 2026 to $200 billion from approximately $130 billion in 2025, indicating strong confidence in future growth while raising investor concerns over high spending.
- Stock Price Volatility: Although Amazon shares rose 0.27% on Friday, they have declined about 17.5% over the past month and are hovering near their lowest level since May 2025, reflecting market caution regarding the company's future performance.
- Market Sentiment Shift: Retail sentiment on Stocktwits has shifted from 'extremely bullish' to 'bullish' in the past 24 hours, with a 35% increase in discussions, indicating a divergence in investor opinions about the stock's trajectory.
- Industry Investment Trends: Amazon's capital expenditure plans align with other major tech companies, which collectively plan to invest over $630 billion in AI buildouts in 2026, highlighting strong expectations for AI demand despite investor concerns about massive expenditures.
See More
Bio-Techne Corporation Q2 2026 Earnings Insights
- Stable Performance: Bio-Techne reported total revenue of $295.9 million for Q2, flat year-over-year, despite headwinds from two large cell therapy customers with FDA Fast Track designations, indicating a balance of short-term challenges and long-term potential in the market.
- Margin Improvement: Adjusted operating margins expanded by approximately 100 basis points year-over-year to 31.1%, reflecting effective strategies in cost management and product mix optimization, which are expected to further enhance profitability in the future.
- Core Business Growth: The four key verticals—cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools—now represent 47% of total revenue, up from 32% in fiscal 2020, demonstrating the company's agile response to strategic investments and changing market demands.
- Outlook: Management anticipates that Q3 organic growth will be consistent with Q2; however, excluding customer-specific cell therapy and OEM headwinds, underlying growth for the remainder of the business is expected to reach mid-single digits, reflecting confidence in future market recovery.
See More
Bio-Techne Declares Quarterly Dividend of $0.08
- Dividend Stability: Bio-Techne declares a quarterly dividend of $0.08 per share, maintaining this amount for 46 consecutive quarters, which demonstrates the company's reliability in shareholder returns and enhances investor confidence.
- Yield Performance: The forward yield of 0.5% may be relatively low, yet it still provides an attractive option for income-seeking investors in the current market environment, potentially encouraging long-term shareholder retention.
- Payment Schedule: The dividend is payable on February 27, with a record date of February 16 and an ex-dividend date of February 12, providing investors with clear cash flow expectations that may enhance market liquidity.
- Financial Performance Beat: Bio-Techne's recent non-GAAP EPS of $0.46 exceeded expectations by $0.03, with revenue of $295.88M surpassing estimates by $5.41M, indicating the company's ongoing growth potential in both revenue and profitability.
See More
Bio-Techne Q2 Earnings Exceed Expectations
- Strong Earnings Performance: Bio-Techne reported a Q2 Non-GAAP EPS of $0.46, beating expectations by $0.03, which reflects the company's ongoing improvement in profitability and boosts investor confidence.
- Slight Revenue Decline: The revenue of $295.88 million, down 0.4% year-over-year, still surpassed market expectations by $5.41 million, indicating the company's ability to maintain relatively stable revenue performance amid challenges.
- Operational Efficiency Improvement: The adjusted operating margin reached 31.1%, an increase of 100 basis points compared to the prior year, showcasing effective productivity and cost containment measures that further enhance profitability.
- Growth in APAC Market: Strong commercial execution and improving market conditions in China and the APAC region led to growth for the third consecutive quarter, demonstrating the ongoing potential of this market segment.
See More
